Industry & Policy News

[Amgen] Amgen announced that the US FDA has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD).

[ohnson & Johnson] Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved an indication extension of DARZALEX® subcutaneous formulation in the frontline setting.

[Science] The now-rescinded policy, designed to protect government researchers from political pressure, strongly endorsed DEI in science

[Astrazeneca] AstraZeneca’s Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer.

[Yagrit (Globe Newswire)] Yaqrit announced a major £2.2 million clinical research grant that will fund the development of its extracorporeal liver support device, DIALIVE for advanced liver disease patients and move the device closer to UKCA and CE mark for marketing authorization.

[Regeneron Pharmaceuticals, Inc. ] Regeneron Pharmaceuticals, Inc. and Sanofi announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent® for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy.